STAT's Readout LOUD podcast discusses Pfizer's woes, explains RFK Jr.'s 'MAHA' campaign, and mulls the latest about the Novo ...

Dick Durbin (D-Ill.) demanded answers from Pfizer and Eli Lilly about their relationships with the telehealth prescribers ...

Activist investor Starboard met with Pfizer last week. Here's what went down, according to the hedge fund's cofounder and CEO ...

The activist investor claims Pfizer failed to capitalize on the windfall earned from its COVID-19 vaccine and, in the process, destroyed tens of billions of dollars in market value.

Leif Johansson, chairman of AstraZeneca, commented on the news: "We note Pfizer's confirmation that it no longer intends to make an offer for AstraZeneca. We welcome the opportunity to continue ...

Pfizer’s transition from pandemic reliance to growth in oncology and rare diseases reflects a strategic pivot, supported by recent acquisitions, despite the challenge of rising debt ...

Pfizer appointed a former chief executive officer at Vanguard, the drug giant's biggest investor, to its board on Tuesday as ...

Barely three years since its coronavirus vaccine helped stem the pandemic, Pfizer’s stock has lost 50 percent of its value ...

covering some of the most notable news stories of the time. Beata Zawrzel / NurPhoto via Getty Images Pfizer is withdrawing all of its sickle cell disease drug, Oxbryta, worldwide because of ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Pfizer (PFE) reports results for the quarter ended September 2024. While this widely-known consensus outlook is ...

Shares of Pfizer (PFE) were trading largely flat at around 5:50 p.m. ET following the news. Oxbryta was approved by the FDA in 2019. The product is also approved for use in over 35 countries ...

(Bloomberg) -- Pfizer Inc. has raised about £2.4 billion ... according to terms of the deal seen by Bloomberg News. The oversubscribed offering was priced at £3.80 per share, a discount of ...